Zghoul N, Fuchs R, Lehr C M, Schaefer U F
Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, D-Saarbrücken.
ALTEX. 2001;18(2):103-6.
Excised human skin has so far been considered to be one of the most suitable in vitro methods to evaluate the penetration of dermatologically applied substances. The limited supply and the relatively high donor variability stimulated many research groups to use animal skin as a substitute for human skin. Since nowadays reconstructed skin equivalents are commercially available, we examined these cultures for their suitability as a percutaneous absorption model for different pharmaceutical formulations. One such equivalent is EpiDerm (EPI-606, MatTek corporation, Ashland Massachusetts) which was investigated using the lipophilic model drug flufenamic acid. Permeation studies with the Franz diffusion cell were undertaken to evaluate the model for the establishment of a new in vitro method to study the percutaneous absorption of different dosage forms. The drug was applied in two pharmaceutical formulations to the intact surface of the skin disk: dissolved in wool alcohol ointment (0.1125 %), and dissolved in Soerensen phosphate buffer pH 7.4 (0.1125% solution). HPLC was used for the analysis of drug content. It was shown that the model forms a barrier towards diffusion by comparing the permeation across the tissue-free inserts to the equivalents. Flux values were calculated and the permeation across the skin equivalent from the solution was noted to be almost forty times higher than from the ointment. Two different batches of the skin equivalent showed no statistically significant difference. Finally the permeability of the reconstructed skin was compared to human epidermis, and a five times higher flux value was found for the skin equivalent model. Our results suggest that reconstructed skin equivalents based on human keratinocytes have potential as a pharmaceutical test system to study dermal drug transport from topical formulations.
迄今为止,切除的人体皮肤一直被认为是评估皮肤科应用物质渗透情况的最适宜的体外方法之一。由于人体皮肤供应有限且供体差异相对较大,许多研究团队开始使用动物皮肤来替代人体皮肤。鉴于如今已可商购重组皮肤替代物,我们对这些培养物作为不同药物制剂经皮吸收模型的适用性进行了研究。其中一种替代物是EpiDerm(EPI - 606,MatTek公司,马萨诸塞州阿什兰),我们使用亲脂性模型药物氟芬那酸对其展开了研究。采用Franz扩散池进行渗透研究,以评估该模型用于建立一种研究不同剂型经皮吸收的新体外方法的可行性。将药物以两种药物制剂的形式应用于皮肤盘的完整表面:溶解于羊毛醇软膏(0.1125%)中,以及溶解于pH 7.4的索伦森磷酸盐缓冲液(0.1125%溶液)中。采用高效液相色谱法分析药物含量。通过比较无组织插入物与皮肤替代物之间的渗透情况,结果表明该模型对扩散形成了屏障。计算了通量值,发现从溶液中穿过皮肤替代物的渗透率比从软膏中的渗透率高近40倍。两批不同的皮肤替代物之间未显示出统计学上的显著差异。最后,将重组皮肤的渗透率与人体表皮进行了比较,发现皮肤替代物模型的通量值高5倍。我们的结果表明,基于人角质形成细胞的重组皮肤替代物有潜力作为一种药物测试系统,用于研究局部制剂的皮肤药物转运。